Interaction of low molecular weight heparin with ketorolac

Journal of Laboratory and Clinical Medicine

Volumn 127, Issue 6, 1996, Pages 583-587

  Green, David ^a   Klement, Petr ^a   Liao, Peng ^a   Weitz, Jeffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030174278     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90149-3     Document Type: Article

References (19)

1. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
2. Buckley MM-T, Brogden RN. Ketorolac: review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;39:86-109.
3. AMA Drug Evaluations. Ketorolac tromethamine. Pain I:32-33, 1994.
4. Roe RL, Bruno JJ, Ellis DJ. Effects of new nonsteroidal antiinflammatory agent on platelet function in male and female subjects [Abstract]. Clin Pharmacol Ther 1981;29:277.
5. Spowart K, Greer IA, McLaren M, Lloyd J, Bullingham RES, Forbes CD. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. Thromb Haemost 1988;60:382-6.
6. Conrad KA, Fagan TC, Mackle MJ, Mayshar PV. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther 1988;43:542-6.
7. Rosen DMB. Ketorolac. Med J Aust 1993;159:490.
8. Ingerman-Wojenski CM, Silver MJ. A quick method for screening platelet dysfunctions using the whole blood Lumi-Aggregometer. Thromb Haemost 1984;51:154-6.
9. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity adding purified antithrombin III. Thromb Res 1977;10:399-410.
10. Bruning JL, Kintz BL. Computational handbook of statistics. Glenview, Illinois: Scott, Foresman and Co., 1977.
11. Ingerman-Wojenski CM, Smith JB, Silver MJ. Difficulty in detecting inhibition of platelet aggregation by the impedance method. Thromb Res 1982;28:426-32.
12. Ingerman-Wojenski CM, Smith JB, Silver MJ. Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets. J Lab Clin Med 1983;101:44-52.
13. Russel-Smith NC, Flower RJ, Cardinal DC. Measuring platelet and leucocyte aggregation/adhesion responses in very small volumes of whole blood. J Pharmcol Methods 1981;6: 315-33.
14. Toon S, Holt BL, Mullin GP, et al. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990;30:743-50.
15. Fragen RJ, Stulberg SD, Wixson R, Glisson S, Librojo E. Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty. J Bone Joint Surg 1995;77A:998-1002.
16. Weale A, Warwick D, Durant N, Prothero D. Is there a clinical interaction between low-molecular-weight heparin and non-steroidal analgesics after total hip replacement? Ann Royal Coll Surg 1995;77:35-7.
17. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982;59:1239-45.
18. 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombosis. J Clin Invest 1993;91:1343-50.
19. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-4.